Drug Trial Radar · NCT06246552
Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines
Last checked: Nov 19, 2026Latest source record: Aug 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
480
Actual
Start
Oct 26, 2024
Primary completion
Jun 5, 2025
Study completion Jun 5, 2025
Sponsor
- Lead sponsor
- Jetema USA Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is Multicenter, Randomized, Double-blind, Placebo-controlled, Single-dose Study to evaluate Safety and Efficacy of JTM201 in patients with Moderate or Severe Glabellar Lines
Conditions
- Glabellar Lines
Interventions
JTM201Biological
JTM201 20U in 0.5mL : JTM201 will be injected via IM in 5 glabellar location 0.1mL (4U / 0.1mL) at each location
PlaceboBiological
Placebo 20U in 0.5mL : Placebo will be injected via IM in 5 glabellar location 0.1mL (4U / 0.1mL) at each location
Primary outcomes
What the sponsor says the trial is designed to measure.
- TEAETime frame: 180 days
- SAETime frame: 180 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ablon Skin Institute & Research Center
Manhattan Beach, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.